150 likes | 197 Views
Discover the significant impact of short hairpin RNAs (shRNAs) in biology and medicine, from their invention in the early 2000s to their application in large-scale screens and in vivo studies. Explore the challenges and potential of shRNAs, including the need for validation, controlling off-target effects, and viral delivery methods for therapeutic applications. Learn about the progress in clinical trials with shRNAs compared to siRNA and the promising future of shRNA therapeutics.
E N D
Short hairpin RNAs Dave Lyons May 2009
Short hairpin RNAs • Discovery of interfering RNAs • shRNAs in biology • shRNAs in medicine
Short hairpin RNAs • Discovery of interfering RNAs • shRNAs in biology • shRNAs in medicine
Discovery of RNAi . . . 1990 2000 2010
“Invention” of shRNA 2000 2010 Paddison et al. 2002
“Invention” of shRNA Paddison et al. 2002; Rao et al. 2009
Short hairpin RNAs • Discovery of interfering RNAs • shRNAs in biology • shRNAs in medicine
shRNA in biological research • Large-scale screens • In vivo studies • Validation
shRNAs for large-scale screens Dykxhoorn and Lieberman 2005
2.) Transplantation of infected SCs 3.) Infect mouse with vector shRNAs for in vivo studies 1.) Mouse KO / KI / BAC Dykxhoorn and Lieberman 2005
Pol III promoter Pol II promoter shRNAs for in vivo studies 4.) Tail vein injection Dykxhoorn and Lieberman 2005; Giering et al. 2008
shRNA - validation 4.) Tail vein injection Off-target effects? Pol III promoter Pol III promoter Pol II promoter Pol II promoter Dykxhoorn and Lieberman 2005; Giering et al. 2008
shRNA - validation 1.) need a phenotypic assay to accurately confirm on-target effect. 2.) need to control for specific and non-specific off-target effects. - expression profiling of transfected controls - general immune response? - bottleneck effects (e.g. nuclear export)
Short hairpin RNAs • Discovery of interfering RNAs • shRNAs in biology • shRNAs in medicine
shRNA in medicine • shRNA is difficult to deliver without viruses but in vivo experiments in mouse suggest better overall for specificity than siRNA. • Successful viral targeting is central to future of shRNA therapeutics. • Clinical trials with siRNA outnumber shRNA currently.